Oculis Holding AG (OCS) Non-Current Debt (2021 - 2024)
Oculis Holding AG (OCS) posted quarterly Non-Current Debt of $127.1 million for Q4 2022, up 3.26% year-over-year from $123.1 million in Q4 2021, and up 3.26% quarter-over-quarter from $123.1 million in Q4 2021.
Powered by 
Analysis
Oculis Holding AG (OCS) Non-Current Debt (2021 - 2024) Analysis & Trends
Oculis Holding AG's Non-Current Debt history runs 2 years deep, the most recent figure standing at $127.1 million for Q4 2022.
- In Q4 2022, Non-Current Debt rose 3.26% year-over-year to $127.1 million; the TTM figure through Dec 2022 stood at $127.1 million (up 3.26% YoY), while the FY2022 annual figure was $128.4 million, up 3.34% from the prior year.
- Non-Current Debt for Q4 2022 stood at $127.1 million, up from $123.1 million in the prior quarter.
- The five-year high for Non-Current Debt was $127.1 million in Q4 2022, with the low at $123.1 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 433,067.91 |
| Dec 31, 2023 | 426,139.99 |
| Sep 30, 2023 | 426,821.52 |
| Dec 31, 2022 | 127.10 Mn |
| Dec 31, 2021 | 123.09 Mn |